NEW YORK, July 26 (Reuters) - Indivior ( INDV ) reached
an $86 million settlement with 16 U.S. states over the drug
manufacturer's alleged role in spreading opioid addiction across
the United States, New York Attorney General Letitia James said
on Friday.
James said the settlement in principle concerned Indivior's ( INDV )
manufacture of buprenorphine-based products meant to treat
opioid abuse, but which allegedly can fuel addiction if misused.
The North Chesterfield, Virginia-based company was
accused of improperly targeting sales to doctors running pill
mills and failing to monitor suspicious orders, leading to
inappropriate prescriptions.
Indivior's ( INDV ) buprenorphine-based products include
Sublocade
and
Suboxone
.
"When companies like Indivior ( INDV ) exploit those in the
thralls of addiction for profit, their behavior must be
stopped," James said in a statement.
She said the $86 million will be used over five years
for opioid addiction treatment, recovery and prevention.
Indivior ( INDV ) did not immediately respond to requests for
comment.
It said on Thursday it
set aside
$75 million for an expected settlement, reflecting the net
present value of the payout. A final settlement must still be
negotiated.
More than 800,000 people in the United States
died of opioid overdoses
between 1999 and 2023, the U.S. Centers for Disease Control
and Prevention has said.
Indivior ( INDV ) remains a defendant in more than 400 civil
lawsuits accusing manufacturers, distributors and retailers of
ignoring red flags about how opioids have been prescribed and
used, and marketing them improperly as a safe means to treat
chronic pain.
Reckitt Benckiser ( RBGPF ) spun off Indivior ( INDV ) in 2014.
Both companies have offices in Slough, England.
James said the Indivior ( INDV ) settlement was negotiated by her
office and the attorneys general of Illinois, Tennessee, Utah
and Virginia.
California, Colorado, Delaware, Georgia, Idaho, Iowa,
Massachusetts, North Carolina, Ohio, Oregon and Vermont were
also involved.